Table 1 Sociodemographic and clinical data of the control subjects (n = 20), people living with HIV-1 with therapeutic success (PLHIV-1s, n = 40) and people living with HIV-1 with therapeutic failure (PLHIV-1f, n = 50). Healthy control subjects and PLHIV-1 under ARV treatment for at least 6 months were recruited at the University hospital of Abomey-Calavi/Sô-Ava between October 2021 and April 2022
Characteristics | Healthy controls | PLHIV-1s | PLHIV-1f | Total number or median for all PLHIV-1 | p-value |
|---|---|---|---|---|---|
Number | 20 | 40 | 50 | 110 | - |
Sex | |||||
Female, n (%) | 9 (45) | 28 (70) | 37 (74) | 74 | - |
Male, n (%) | 11 (55) | 12 (30) | 13 (26) | 36 | - |
Median age [IQR] | 39.5 [35.25–43] | 45 [36.25–50.50] | 40 [32.75–45.25] | 41 [35.75–48.00] | ap = 0.21 |
Median viral load (Log) [IQR] | ND | U | 4.56 [3.9–5.1] | 4.56 [3.9–5.1] | - |
ARV treatment | |||||
TDF + 3TC + EFV, n (%) | - | 15 (37.5) | 37 (74) | 52 | - |
TDF + 3TC + DTG, n (%) | - | 25 (62.5) | 13 (26) | 38 | - |
Median CD4 + T cell count (cells/µl) [IQR] | ND | 301 [205–508.5] | 269 [148–417.5] | 283 [176.3–433] | bp = 0.21 |
ARV Treatment duration (months) [IQR] | - | 60 [23–196] | 62 [14–192] | - | − |